查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1835361

腹腔內感染疾病市場（按抗生素類別、感染類型、病原體類型、患者年齡層和最終用戶分類）—2025-2032 年全球預測

Intra-abdominal Infections Market by Antibiotic Class, Infection Type, Pathogen Type, Patient Age Group, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腹腔內感染疾病市場將成長 497 億美元，複合年成長率為 9.20%。

主要市場統計數據
基準年2024年 245.7億美元
預計2025年 268.6億美元
預測年份：2032年 497億美元
複合年成長率（%） 9.20%

腹腔內感染疾病種類繁多，從簡單的局部發炎過程到複雜的、危及生命的多菌性膿毒症，不一而足。臨床醫生面臨社區獲得性感染和院內感染的混合感染，這些感染的來源、宿主因素和微生物學各不相同。因此，早期發現和及時控制感染源仍然是有效管理的基礎，抗生素的選擇必須在經驗性擴大用藥量和根據培養和藥敏數據逐漸減量之間取得平衡。

診斷的複雜性源自於重疊的臨床表現、差異化的培養產量以及不斷變化的抗藥性模式。影像學檢查、手術評估和腹膜培養至關重要，但每種檢查都存在局限性，會影響治療時機。同時，主要病原體中的抗菌藥物抗藥性正在改變經驗性治療方案，促使重症病例依賴更高級的藥物和組合方案。這些變化促使人們需要協調一致的抗菌藥物管理、多學科治療途徑和強力的醫院監測，以保留治療方法方案並最佳化治療結果。

因此，臨床、營運和商業領域的相關人員必須在及時診斷、綜合管理和供應鏈連續性等優先事項上達成一致。透過了解推動治療決策的臨床細微差別和系統壓力，領導者可以更好地設計干預措施，以降低發病率、縮短住院時間，並限制不必要的廣譜抗生素暴露帶來的附帶危害。

快速變革正在改變腹腔內感染管理的臨床、診斷和給藥動態

由於抗菌藥物抗藥性、技術進步和醫療服務模式的轉變，腹腔內感染管理模式正在發生快速且顯著的變化。抗藥性趨勢正在重塑經驗性處方模式，並提升了那些對多重抗藥性革蘭氏陰性菌具有活性的藥物的臨床和經濟價值。同時，快速診斷和分子病原體檢測的創新正在縮短從就診到標靶治療的間隔時間。

醫療保健服務的轉型同樣影響深遠。門診手術中心的興起，以及向更早出院和門診腸外抗生素治療的轉變，正在改變患者流量和藥物利用，需要住院團隊和社區醫療保健組織之間建立新的合作。監管部門對管理和報告的期望不斷變化，更加重視可衡量的指標和專案課責，這使得這些轉變變得更加複雜。因此，相關人員面臨著這樣一種局面：臨床有效性、供應可靠性和對管理的遵守程度既決定了病人的治療結果，也決定了組織的風險。

這些綜合因素需要適應性策略，整合新的診斷方法、管理通訊協定和供應鏈彈性，同時在關鍵決策點保留臨床醫師的自主權。積極調整臨床路徑、採購慣例和監測能力的組織將更有能力管理複雜性，並長期維持治療方案。

2025年美國關稅調整對抗生素供應鏈、醫院採購慣例和臨床可近性的預期影響

圍繞貿易和關稅的政策環境會對抗生素、生產投入以及腹腔感染治療所必需的醫療用品的成本結構和供應產生重大影響。進口關稅和貿易壁壘的變化會改變原料藥和成品藥的生產經濟性，進而影響醫院和經銷商的籌資策略。實際上，當關稅變化擾亂現有的供應鏈時，採購團隊可能會面臨供應商選擇受限、前置作業時間延長以及某些靜脈注射抗生素和腸外製劑採購成本上升的問題。

臨床醫師和藥局負責人必須預見醫院處方集和治療指引變化所帶來的副作用。當有採購限制或價格壓力時，醫院通常會重新評估處方集中的藥物，替代臨床等效藥物或調整管理政策以維持關鍵庫存。這些營運回應需要明確的臨床管治，以防止意外後果，例如經驗性應用不足或高風險患者替換不當。

此外，製造商和契約製造製造商可以透過轉移生產地點、重新設計供應合約以及加快對區域製造業的投資來緩解關稅的影響，以應對利潤壓力。此類策略調整將提升長期韌性，但會帶來短期波動。因此，在關稅導致供應鏈中斷的情況下，結合採購預測、庫存緩衝和持續臨床監測的跨職能規劃對於維持藥品供應和臨床完整性至關重要。

跨抗生素類別、感染疾病狀況、病原體概況、年齡層和醫療保健環境的細分臨床和商業性洞察

細緻的細分視角揭示了治療方法選擇、感染疾病格局、病原體概況、患者人口統計特徵和醫療保健環境如何相互交織，共同塑造臨床和商業動態。根據抗生素類別，臨床醫生使用卡巴培南類、頭孢菌素類和青黴素類抗生素來涵蓋廣泛的腹膜內病原體。在卡巴培南類抗生素中，根據病原體疑似情況、組織穿透需求和抗藥性模式，使用多利培南、厄他培南、Imipenem/西司他丁和美Meropenem等藥物。頭孢菌素類藥物分為第三代頭孢菌素（例如頭孢噻肟和頭孢曲松）和第四代頭孢菌素，每種藥物的選擇都基於其對特定革蘭氏陰性菌的覆蓋能力，以及在必要時穿透中樞神經系統的能力。青黴素組合藥物，例如Ampicillin/舒巴坦和哌拉西林/他唑巴坦，在社區獲得性病菌感染的經驗性治療和許多機構方案中發揮重要作用。

社區型感染和院內獲得性感染分為複雜感染和非複雜感染，因此治療需求也不同。社區型感染通常分為複雜感染和非複雜感染，對於近期無醫療保健暴露的患者，經驗性治療的範圍通常較小。相反，無論是在 ICU 還是手術後，院內感染疾病都需要更廣泛的經驗性治療方案，因為多重抗藥性細菌的風險增加。主導病原體的見解區分了厭氧菌（如脆弱擬桿菌屬和梭菌屬）、革蘭氏陰性菌（如腸桿菌科和銅綠假單胞菌）和革蘭氏陽性菌（如腸球菌屬和金黃色葡萄球菌），每種細菌都帶來不同的經驗性和確定性治療選擇和管理挑戰。

成人、老年人和兒童的藥物動力學和安全性考量各不相同，這些因素會影響劑量、製劑選擇和監測。最後，雖然醫院分為二級和三級醫療機構，但門診醫療中心和醫院之間最終用戶的細分決定了資源的可用性、高級診斷服務的可及性以及源頭管理的程序能力。這些相互交叉的細分領域需要量身定做的臨床路徑、籌資策略和教育計劃，以確保每個患者群體都能獲得最佳的、針對特定情況的照護。

美洲、中東和非洲以及亞太地區政策的多樣性影響著治療模式、供應鏈彈性和臨床反應

區域差異對臨床實務、供應鏈物流和政策環境有著重大影響，決定醫療服務提供者和衛生系統應對腹腔內感染的方式。在美洲，治療方案和管理框架越來越強調實證經驗性治療方法選擇以及在高級急診中心整合快速診斷技術，而供應鏈整合和集團採購組織則影響著處方決策和價格談判。這些動態正在推動臨床領導層和採購部門之間的協調，以確保關鍵藥物的持續供應。

歐洲、中東和非洲地區醫療基礎設施、法律規範和抗菌藥物抗藥性狀況各異，導致其優先事項也各有不同。資源豐富的機構專注於快速分子診斷和先進的管理項目，而資源匱乏的機構則優先考慮獲得基本抗生素、基本影像和手術能力。政策層面的干涉措施和區域合作在支持這一多元化地區的抗菌藥物管理和抗藥性監測方面發揮更大的作用。

亞太地區臨床需求旺盛，技術應用迅速，國內生產能力多樣化。雖然區域製造商可以在一定程度上緩解供應中斷的影響，但需求壓力和韌性趨勢需要協調一致的國家管理和採購策略。在所有地區，監管、生產地理和臨床實踐之間的相互作用將決定短期營運選擇以及供應和治療方法方案的長期韌性。

競爭與合作格局突顯抗感染疾病治療領域的製造能力、診斷創新與策略夥伴關係

腹腔內感染疾病相關治療方法和服務的競爭格局呈現出老牌製藥商、契約製造製造商、診斷創新者和臨床服務供應商的混合格局。老牌製藥商通常專注於維護可靠的供應線、延長產品生命週期，並透過教育和處方支援來支援舉措計劃。契約製造製造商和專業的無菌注射生產設施在確保腸外抗生素的供應方面發揮著至關重要的作用，為策略夥伴關係關係和產能投資創造了機會。

隨著快速識別技術和藥敏平台直接改變處方行為並縮短最佳治療時間，診斷公司和醫院實驗室網路的影響力日益增強。診斷供應商與臨床領導者之間的合作可以帶來路徑層面的改進，從而減少不適當的頻譜使用並加快標靶治療。此外，支持門診腸外抗生素治療和出院後監測的服務供應商延長了護理的連續性，使其能夠在不犧牲安全性的情況下更早地從住院過渡。

製藥商、診斷公司和醫療保健系統之間的策略聯盟可以提供將可靠的抗生素供應與診斷管理相結合的綜合服務。此類合作也支持透過數據共用、處方最佳化以及針對處方醫生和護理團隊的有針對性的教育，共同應對抗生素抗藥性問題。

為醫療保健領導者提供可操作的優先建議，以改善臨床結果、保留治療方法選擇並增強供應彈性

醫療保健領導者應採取一系列切實可行的優先行動，以提升臨床療效、維持治療可近性並降低供應風險。首先，協調採購和臨床管治，並定期對處方集選擇、庫存風險和臨床可接受的替代治療方法進行跨職能審查，以確保在供應波動的情況下保持連續性。其次，加速採用快速診斷工具，並將明確的降階梯方案納入護理路徑，以便在適當的情況下快速確定經驗性頻譜治療方案，降低抗藥性選擇壓力，並節省更高級的通訊協定。

第三，我們將擴大門診腸外抗生素治療，並加強出院協調，以在確保安全的同時縮短住院時間。第四，我們將實施分級管理指標，考慮感染疾病類型、病原體風險和患者年齡，並將教育和審核工作重點放在臨床影響最大的領域。第五，我們將透過多年期合約、盡可能的雙重採購以及緊急時應對計畫，積極與製造商和委託製造合作，以緩解關稅和中斷相關的短缺。最後，我們將投資於勞動力發展，使外科團隊、加護治療醫師、藥劑師和感染疾病專家具備實施快速供應管理、劑量最佳化和協調追蹤的技能。

這些行動共同平衡了當前的營運彈性和長期管理目標，使組織能夠提供高品質的護理，同時保持治療效果。

一種強大的混合方法研究途徑，整合了原始臨床資訊、操作數據和關於可靠性的嚴格二次證據

本執行摘要所依據的研究採用混合方法，整合了原始臨床數據、機構層面的營運數據和全面的二次研究，以確保得出可靠且基於具體情況的結論。原始數據是透過與外科、重症監護、感染疾病和藥學專業的臨床醫生進行結構化訪談和諮詢討論收集的，並輔以採購和供應鏈專家的協助，以構建營運藍圖。這些第一手觀點有助於制定圍繞藥物選擇、管理實踐和供應應急的方案。

二次研究整合了同行評審文獻、臨床指南、監管文件以及衛生部門公開的監測數據，以基於既定證據得出研究結果。分析了真實世界數據，包括醫院用藥模式、抗生素使用記錄和實驗室藥敏報告，以識別實踐差異和抗藥性趨勢。在適用的情況下，使用資料三角檢驗法，根據可觀察的營運指標檢驗定性見解。

分析方法包括比較臨床路徑圖譜繪製、供應中斷情境敏感度分析以及相關人員影響評估，以確定建議的優先順序。在整個過程中，我們專注於資料來源、調查方法透明度和同儕檢驗，以確保結論反映臨床實際情況並具有操作可行性。

整合策略要點，突顯臨床意義、營運風險和全系統改進的機會

本執行摘要強調了一系列趨同的優先事項：保障有效抗生素的可近性，加速診斷主導醫療服務，以及增強系統層面對供應和政策波動的抵禦能力。臨床上，快速的供應管理和個人化的抗生素治療顯然可以挽救生命，但要持續實現這一目標，需要在診斷、管理基礎設施和跨部門合作方面進行投資。在營運方面，採購和藥房負責人必須預測供應鏈衝擊，並保持靈活的策略，在不損害臨床標準的前提下保護關鍵藥物。

從策略角度來看，市場環境將有利於那些將診斷與治療計劃相結合，並與製造商和服務供應商建立持久夥伴關係以確保供應可靠性的組織。包括關稅調整和不斷變化的監管預期在內的政策變化，持續帶來風險和機會。最終，將洞察轉化為改善患者預後，對於協調臨床路徑、管理目標和採購慣例至關重要，從而使它們在日常護理和危機應對中相輔相成。

將這些優先事項付諸實施的領導者不僅可以減輕眼前的風險，還可以為維持抗生素有效性和改善腹腔內感染患者預後的更廣泛努力做出貢獻。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 對抗多重抗藥性腹膜內病原體的新型BETA-內醯胺酶抑制劑組合的需求不斷成長
  • 擴大採用特異性病原體的快速診斷面板來標靶治療複雜性腹部膿毒症
  • 增加口服分級抗生素治療的投資，以減少腹腔內感染疾病的住院時間
  • 新一代頭孢菌素-BETA-內醯胺酶抑制劑組合的出現擴大了對假單胞菌的應用範圍
  • 擴大針對腹腔內感染疾病的假單胞菌和腸桿菌科細菌的噬菌體療法研發管線

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 腹腔內感染疾病市場（依抗生素類型）

  • 卡巴培南類
    • 多利培南
    • 厄他培南
    • Imipenem/西司他丁
    • Meropenem
  • 頭孢菌素類
    • 第四代
      • 頭孢吡肟
    • 第三代
      • 頭孢噻肟
      • 頭孢曲松
  • 青黴素
    • Ampicillin/舒巴坦
    • 哌拉西林/他唑巴坦

9. 腹腔內感染疾病市場（依感染類型）

  • 社區收購
    • 複雜的
    • 簡單的
  • 院內感染
    • ICU相關
    • 手術後

第10章腹腔內感染疾病市場（依病原體類型）

  • 厭氧
    • 脆弱擬桿菌
    • 梭菌
  • 革蘭氏陰性菌
    • 腸桿菌科
    • 銅綠假單胞菌
  • 革蘭氏陽性
    • 腸球菌
    • 金黃色葡萄球菌

第 11 章。按患者年齡層別分類的腹腔內感染疾病市場

  • 成人
  • 老年人
  • 孩子們

第 12 章。腹腔內感染疾病市場（按最終用戶）

  • 門診治療中心
  • 醫院
    • 二級護理
    • 三級護理

13. 腹腔內感染疾病市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章腹腔內感染疾病市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 腹腔內感染疾病市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Pfizer Inc.
    • Sandoz International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals PLC
    • Allergan plc
    • GlaxoSmithKline plc
    • Cipla Limited
    • Lupin Limited
Product Code: MRR-43127F7279D5

The Intra-abdominal Infections Market is projected to grow by USD 49.70 billion at a CAGR of 9.20% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 24.57 billion
Estimated Year [2025] USD 26.86 billion
Forecast Year [2032] USD 49.70 billion
CAGR (%) 9.20%

Intra-abdominal infections represent a heterogeneous group of conditions that span simple localized inflammatory processes to complex, life-threatening polymicrobial sepsis. Clinicians confront a mix of community-acquired and hospital-acquired presentations that vary by source, host factors, and microbiology. As a result, early recognition and rapid source control remain the cornerstones of effective management, while antimicrobial selection must balance empiric breadth with de-escalation guided by culture and sensitivity data.

Diagnostic complexity stems from overlapping clinical presentations, variable culture yields, and evolving resistance patterns. Imaging, surgical assessment, and peritoneal cultures are critical, yet each has limitations that influence therapeutic timing. Concurrently, antimicrobial resistance among key pathogens has altered empirical therapy algorithms, prompting greater reliance on higher-tier agents and combination regimens in severe cases. These changes amplify the need for coordinated antimicrobial stewardship, multidisciplinary care pathways, and robust hospital surveillance to preserve therapeutic options and optimize outcomes.

Stakeholders across clinical, operational, and commercial domains must therefore align on priorities that include timely diagnostics, stewardship integration, and supply chain continuity. By understanding the clinical nuances and system pressures that drive treatment decisions, leaders can better design interventions that reduce morbidity, shorten hospital stays, and limit the collateral harm of unnecessary broad-spectrum antibiotic exposure.

Rapid Transformations Reshaping Clinical Practice, Diagnostics, and Supply Dynamics in Intra-abdominal Infection Management

The landscape of intra-abdominal infection management is undergoing rapid and consequential shifts driven by antimicrobial resistance, technological advances, and changes in care delivery models. Resistance trends are reshaping empiric prescribing patterns and elevating the clinical and economic value of agents with retained activity against multidrug-resistant Gram-negative organisms. Simultaneously, innovations in rapid diagnostics and molecular pathogen detection are beginning to shorten the interval between presentation and targeted therapy, enabling faster de-escalation when appropriate and reducing unnecessary exposure to broad-spectrum agents.

Care delivery transformations are equally impactful. Growth in ambulatory surgical centers and shifts toward earlier discharge and outpatient parenteral antimicrobial therapy have altered patient flows and medication utilization, requiring new coordination between inpatient teams and community providers. These transitions are compounded by evolving regulatory expectations for stewardship and reporting, which place a premium on measurable metrics and program accountability. As a result, stakeholders face a landscape where clinical efficacy, supply reliability, and stewardship compliance converge to determine both patient outcomes and organizational risk.

Taken together, these forces demand adaptive strategies that integrate novel diagnostics, stewardship protocols, and supply chain resilience while maintaining clinician autonomy in critical decision moments. Organizations that proactively align clinical pathways, procurement practices, and surveillance capabilities will be better positioned to manage complexity and sustain therapeutic options over the long term.

Anticipated Effects of United States Tariff Adjustments on Antibiotic Supply Chains, Hospital Procurement Practices, and Clinical Access in 2025

The policy environment surrounding trade and tariffs can materially influence the cost structure and availability of antimicrobial agents, manufacturing inputs, and medical supplies integral to intra-abdominal infection care. Changes to import duties and trade barriers alter manufacturing economics for active pharmaceutical ingredients and finished dosage forms, which in turn affect procurement strategies for hospitals and distributors. In practical terms, procurement teams may experience narrower supplier options, increased lead times, and higher acquisition costs for select intravenous antibiotics and parenteral formulations when tariffs disrupt established supply chains.

Clinicians and pharmacy leaders should anticipate secondary effects that manifest as alterations in hospital formularies and therapeutic guidelines. When sourcing constraints or price pressures exist, hospitals commonly reassess formulary inclusions and may substitute clinically equivalent agents or adjust stewardship policies to preserve critical stock. These operational responses require clear clinical governance to prevent unintended consequences such as suboptimal empiric coverage or inappropriate substitution in high-risk patients.

Moreover, manufacturers and contract manufacturers may respond to tariff-driven margin pressures by relocating production, redesigning supply agreements, or accelerating investments in regional manufacturing to mitigate exposure. Such strategic adaptations can improve long-term resilience but create short-term volatility. Therefore, cross-functional planning that combines procurement forecasting, inventory buffering, and continual clinical oversight is essential to maintain access and clinical integrity in the face of tariff-induced supply chain disruption.

Segment-Level Clinical and Commercial Insights Spanning Antibiotic Classes, Infection Presentations, Pathogen Profiles, Age Cohorts, and Healthcare Settings

A nuanced segmentation lens reveals how therapeutic choices, infection contexts, pathogen profiles, patient demographics, and care settings intersect to shape clinical and commercial dynamics. By antibiotic class, clinicians rely on carbapenems, cephalosporins, and penicillins to cover the broad spectrum of intra-abdominal pathogens. Within carbapenems, agents such as doripenem, ertapenem, imipenem/cilastatin, and meropenem are deployed based on pathogen suspicion, tissue penetration requirements, and resistance patterns. Cephalosporin use differentiates between third-generation options like cefotaxime and ceftriaxone and fourth-generation cefepime, each selected for specific Gram-negative coverage and central nervous system penetration when indicated. Penicillin-based combinations, including ampicillin/sulbactam and piperacillin/tazobactam, retain an important role for community-acquired polymicrobial infections and as empiric therapy in many institutional protocols.

Infection type segmentation between community-acquired and hospital-acquired presentations changes therapeutic imperatives. Community-acquired cases, subdivided into complicated and uncomplicated forms, often permit narrower empiric coverage when patients present without recent healthcare exposure. Conversely, hospital-acquired infections, whether associated with ICU care or post-surgical settings, demand broader empiric regimens because of increased risk of multidrug-resistant organisms. Pathogen-driven insight distinguishes anaerobic organisms such as Bacteroides fragilis and Clostridium species from Gram-negative pathogens including Enterobacteriaceae and Pseudomonas aeruginosa, and from Gram-positive agents like Enterococcus species and Staphylococcus aureus, each of which drives different empiric and definitive therapy choices and stewardship challenges.

Patient age group further modulates therapeutic decisions, as adult, geriatric, and pediatric populations present distinct pharmacokinetic and safety considerations that affect dosing, formulation selection, and monitoring. Finally, end user segmentation between ambulatory care centres and hospitals, with hospitals split into secondary and tertiary care, determines resource availability, access to advanced diagnostics, and procedural capabilities for source control. Collectively, these intersecting segments demand tailored clinical pathways, procurement strategies, and education programs to ensure that each patient cohort receives optimal, context-appropriate care.

Regional Treatment Patterns, Supply Chain Resilience, and Policy Variations Shaping Clinical Responses Across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional variation exerts a profound influence on clinical practice, supply chain logistics, and policy environments, shaping how providers and health systems approach intra-abdominal infections. In the Americas, treatment protocols and stewardship frameworks increasingly emphasize evidence-based empiric selection and the integration of rapid diagnostics in high-acuity centers, while supply chain consolidation and group purchasing organizations influence formulary decisions and pricing negotiations. These dynamics encourage coordination between clinical leaders and procurement to ensure consistent access to critical agents.

In Europe, Middle East & Africa, heterogeneity in healthcare infrastructure, regulatory oversight, and antimicrobial resistance profiles creates divergent priorities. High-resource centers may focus on rapid molecular diagnostics and advanced stewardship programs, whereas resource-constrained settings prioritize access to essential antibiotics, basic imaging, and surgical capacity. Policy-level interventions and regional collaborations play a larger role in supporting antimicrobial stewardship and addressing resistance surveillance in this diverse region.

Asia-Pacific presents a combination of high-volume clinical demand, rapid technological adoption, and varied domestic manufacturing capacity. Regional manufacturers can mitigate some supply disruptions, but demand pressures and resistance trends necessitate coordinated national strategies for stewardship and procurement. Across all regions, the interplay between regulation, manufacturing geography, and clinical practice determines both short-term operational choices and long-term resilience of supply and therapeutic options.

Competitive and Collaborative Company Landscape Highlighting Manufacturing Capacity, Diagnostic Innovation, and Strategic Partnerships in Anti-infective Care

The competitive landscape for therapies and services relevant to intra-abdominal infections is characterized by a mix of established pharmaceutical manufacturers, contract producers, diagnostic innovators, and clinical service providers. Established drug producers often focus on maintaining reliable supply lines, extending product lifecycles, and supporting stewardship initiatives through education and formulary support. Contract manufacturers and specialized sterile injectable plants play a pivotal role in ensuring availability of parenteral antibiotics, creating opportunities for strategic partnerships and capacity investments.

Diagnostic companies and hospital laboratory networks are increasingly influential, as rapid identification technologies and susceptibility platforms directly change prescribing behavior and reduce time to optimal therapy. Collaboration between diagnostic vendors and clinical leaders can yield pathway-level improvements that reduce inappropriate broad-spectrum use and speed targeted therapy. Additionally, service providers that support outpatient parenteral antimicrobial therapy and post-discharge monitoring are expanding the continuum of care, enabling earlier transition from inpatient settings without sacrificing safety.

Strategic alliances between pharmaceutical manufacturers, diagnostic firms, and healthcare systems can create integrated offerings that pair reliable antimicrobial supply with diagnostic stewardship. Such collaboration also supports joint efforts to address antimicrobial resistance through data sharing, formulary optimization, and targeted education for prescribers and care teams.

Actionable and Prioritized Recommendations for Healthcare Leaders to Improve Clinical Outcomes, Preserve Therapeutic Options, and Strengthen Supply Resilience

Healthcare leaders should adopt a set of practical, prioritized actions to strengthen clinical outcomes, maintain therapeutic access, and mitigate supply risks. First, align procurement and clinical governance by instituting regular cross-functional reviews of formulary choices, inventory exposure, and clinically acceptable therapeutic alternatives to ensure continuity in the face of supply variability. Second, accelerate adoption of rapid diagnostic tools and embed explicit de-escalation protocols into care pathways so that empiric broad-spectrum therapy is narrowed promptly when appropriate, reducing resistance selection pressure and conserving higher-tier agents.

Third, expand outpatient parenteral antimicrobial therapy frameworks and strengthen discharge coordination to reduce inpatient length of stay while maintaining safety. Fourth, implement tiered stewardship metrics that account for infection type, pathogen risk, and patient age to target education and audit efforts where they will have the greatest clinical impact. Fifth, engage manufacturers and contract manufacturers proactively through multi-year agreements, dual-sourcing where feasible, and contingency planning to alleviate tariff- or disruption-related scarcity. Finally, invest in workforce training that equips surgical teams, intensivists, pharmacists, and infectious disease specialists with the skills to execute rapid source control, optimized dosing, and coordinated follow-up care.

Taken together, these actions balance immediate operational resilience with long-term stewardship objectives, positioning organizations to deliver high-quality care while preserving therapeutic effectiveness.

Robust Mixed Methods Research Approach Integrating Primary Clinical Input, Real-world Operational Data, and Rigorous Secondary Evidence for Reliability

The research underpinning this executive summary uses a mixed-methods approach that integrates primary clinical inputs, facility-level operational data, and comprehensive secondary research to ensure robust, context-sensitive conclusions. Primary inputs were gathered through structured interviews and advisory discussions with clinicians across surgical, critical care, infectious disease, and pharmacy disciplines, complemented by procurement and supply chain professionals to capture operational realities. These firsthand perspectives informed scenario building around drug selection, stewardship practices, and supply contingencies.

Secondary research synthesized peer-reviewed literature, clinical guidelines, regulatory documents, and publicly available surveillance data from health authorities to ground findings in established evidence. Real-world data sources such as hospital utilization patterns, antimicrobial consumption records, and laboratory susceptibility reports were analyzed to identify practice variation and resistance trends. Where applicable, data triangulation validated qualitative insights against observable operational metrics.

Analytical methods included comparative clinical pathway mapping, sensitivity analysis of supply disruption scenarios, and stakeholder impact assessments to prioritize recommendations. Throughout the process, attention to data provenance, methodological transparency, and expert validation ensured that conclusions reflect clinical reality and operational feasibility.

Synthesis of Strategic Takeaways Emphasizing Clinical Imperatives, Operational Risks, and Opportunities for System-wide Improvement

This executive synthesis highlights a set of converging priorities: protect access to effective antimicrobials, accelerate diagnostic-driven therapy, and reinforce system-level resilience against supply and policy volatility. Clinically, the imperative is clear-prompt source control and tailored antimicrobial therapy save lives, but achieving this consistently requires investments in diagnostics, stewardship infrastructure, and cross-disciplinary coordination. Operationally, procurement and pharmacy leaders must anticipate supply chain shocks and maintain flexible strategies that safeguard critical agents without compromising clinical standards.

Strategically, the market environment rewards organizations that integrate diagnostics with therapeutic planning and that form durable partnerships with manufacturers and service providers to ensure supply reliability. Policy changes, including tariff adjustments and evolving regulatory expectations, will continue to create both risks and opportunities; responsive systems will be those that combine clinical rigor with agile contracting and contingency planning. Ultimately, translating insight into improved patient outcomes depends on aligning clinical pathways, stewardship goals, and procurement practices so that each reinforces the others in routine care and crisis response.

Leaders who operationalize these priorities will not only mitigate immediate risks but also contribute to broader efforts to preserve antimicrobial effectiveness and improve outcomes for patients with intra-abdominal infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for novel B-lactamase inhibitor combinations to combat multidrug-resistant intra-abdominal pathogens
  • 5.2. Increasing adoption of pathogen-specific rapid diagnostic panels for targeted therapy in complex abdominal sepsis
  • 5.3. Growing investment in oral step-down antibiotic regimens to reduce hospital length of stay in intra-abdominal infections
  • 5.4. Emergence of next-generation cephalosporin-B-lactamase inhibitor combinations offering expanded Pseudomonas coverage in intra-abdominal infections
  • 5.5. Expanding pipeline of bacteriophage therapies targeting Pseudomonas and Enterobacteriaceae in intra-abdominal infections

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intra-abdominal Infections Market, by Antibiotic Class

  • 8.1. Carbapenems
    • 8.1.1. Doripenem
    • 8.1.2. Ertapenem
    • 8.1.3. Imipenem/Cilastatin
    • 8.1.4. Meropenem
  • 8.2. Cephalosporins
    • 8.2.1. Fourth Generation
      • 8.2.1.1. Cefepime
    • 8.2.2. Third Generation
      • 8.2.2.1. Cefotaxime
      • 8.2.2.2. Ceftriaxone
  • 8.3. Penicillins
    • 8.3.1. Ampicillin/Sulbactam
    • 8.3.2. Piperacillin/Tazobactam

9. Intra-abdominal Infections Market, by Infection Type

  • 9.1. Community Acquired
    • 9.1.1. Complicated
    • 9.1.2. Uncomplicated
  • 9.2. Hospital Acquired
    • 9.2.1. ICU Associated
    • 9.2.2. Post Surgical

10. Intra-abdominal Infections Market, by Pathogen Type

  • 10.1. Anaerobic
    • 10.1.1. Bacteroides Fragilis
    • 10.1.2. Clostridium Species
  • 10.2. Gram Negative
    • 10.2.1. Enterobacteriaceae
    • 10.2.2. Pseudomonas Aeruginosa
  • 10.3. Gram Positive
    • 10.3.1. Enterococcus Species
    • 10.3.2. Staphylococcus Aureus

11. Intra-abdominal Infections Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Intra-abdominal Infections Market, by End User

  • 12.1. Ambulatory Care Centres
  • 12.2. Hospitals
    • 12.2.1. Secondary Care
    • 12.2.2. Tertiary Care

13. Intra-abdominal Infections Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Intra-abdominal Infections Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Intra-abdominal Infections Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Sandoz International GmbH
    • 16.3.3. Teva Pharmaceutical Industries Ltd.
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. Fresenius Kabi AG
    • 16.3.6. Hikma Pharmaceuticals PLC
    • 16.3.7. Allergan plc
    • 16.3.8. GlaxoSmithKline plc
    • 16.3.9. Cipla Limited
    • 16.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. INTRA-ABDOMINAL INFECTIONS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. INTRA-ABDOMINAL INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRA-ABDOMINAL INFECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2